Lilly factory in New Jersey comes under more federal scrutiny
Lilly said it was working closely with the FDA and the “situation does not affect the quality, safety or supply of any current or planned Lilly products in the marketplace.”
Pharmaceutical
Articles
Novartis gets green light for production of cancer drug in Indy
The 70,000-square-foot facility near Indianapolis International Airport will be used to make Pluvicto, which is used to treat advanced-stage prostate cancer who have run out of treatment options.
Lilly launches online service that offers home delivery of weight-loss, diabetes, migraine drugs
Among the medications listed as available through LillyDirect Pharmacy Services is Zepbound, the company’s popular new weight loss treatment, which is projected to exceed $2 billion in sales in 2024.
Nevada company sues Lilly for breach of contract over Alzheimer’s drug
Lilly called the lawsuit “baseless” and said PDL BioPharma “has no plausible claim to royalties” for donanemab, which is expected to be approved by the FDA this quarter.
2023 Newsmaker: Ricks leads Lilly to new heights
David Ricks led Eli Lilly and Co. to milestone after milestone in 2023, with a slew of product launches for diseases from obesity to inflammatory bowel disease. And when Lilly wasn’t scoring wins in the laboratory, it was issuing a series of head-turning announcements,
Legislative push brewing to make new weight loss drugs more accessible
Obesity drugs like Wegovy and Eli Lilly’s Zepbound are showing promising results in helping people shed pounds. But a law bans Medicare from paying for weight loss drugs. Now, drugmakers and a bipartisan coalition of lawmakers are gearing up to push for that to change next year.
Lilly’s soaring stock, Fishers’ innovation park among top 10 life sciences stories of 2023
It was a busy year for the Indiana life sciences community, with a flurry of billion-dollar deals, major announcements, and a few setbacks. Here we present the top 10 stories of 2023—the good, the bad and the ugly—about an industry that is often hailed as a key driver of Indiana’s economy.
RayzeBio Inc. to be acquired by drugmaker Bristol Myers Squibb for $4.1B
RayzeBio is building a large factory on the northwest side of Indianapolis to make radioisotopes for cancer treatment.
Drugmakers delay in-demand medicines to evade Biden’s new pricing rules
Firms that normally try to sell drugs as soon as possible are suspending clinical trials and shifting timelines, while patient groups are demanding change.
Point Biopharma shares sink 11% on study results; Lilly acquisition still up in air
Results of a clinical trial for Point Biopharma’s lead compound fell short of analysts’ expectations, and that development is likely to pressure its investors to decide whether to agree to sell the company to Eli Lilly and Co. for $1.4 billion.
Lilly stock slips after study finds patients who stop Zepbound regain weight
People who stopped taking Eli Lilly and Co.’s blockbuster drug Zepbound after about eight months regained half the weight they’d lost a year later, yet were significantly thinner than when they had started the obesity drug, according to a new study.
Lilly launches obesity drug, but insurers balk over price
The new drug, called Zepbound, carries a hefty price of $1,059.87 per month, and insurers and health care plans are balking, questioning its affordability. Many employers and government health programs exclude obesity treatments from their coverage.
White House threatens patents of high-priced drugs developed with taxpayer dollars
The Biden administration is putting pharmaceutical companies on notice, warning them that if the price of certain drugs is too high, the government might cancel their patent protection and allow rivals to make their own versions.
CVS to launch reimbursement model to simplify drug pricing
The biggest U.S. drugstore chain aims to make the payment system more transparent by using a formula based on a drug’s cost, a fixed markup, and a fee that reflects the value of the pharmacy services, the company said Tuesday.
In race to develop obesity drugs, Roche acquires California biotech for $2.7B
The company, Carmot Therapeutics, has numerous drugs under development. Its lead asset is a once-a-week injection that is in mid-stage development for the treatment of obesity.
OxyContin maker’s bankruptcy deal hits Supreme Court, with billions at stake
The agreement hammered out with state and local governments and victims would provide billions of dollars to combat the opioid epidemic. The decision also has implications for other major product liability lawsuits settled through the bankruptcy system.
High-stakes dispute between Lilly, competitor over migraine drugs winding down
The two companies have been battling for years over patents for migraine headache drugs—Emgality for Lilly and Anjovy for Teva. Both drugs are once-monthly injections and were approved 13 days apart in September 2018.
Lilly experimental drug lowers heart disease risk factor in just one dose, study finds
Lilly’s lepodisiran, given at the highest dose, reduced a heart disease-linked protein to undetectable levels for 48 weeks, according to the study.
Obesity drug cut risk of serious heart problems by 20%, study finds
The research is the first to document that an obesity medication can not only pare pounds, but also safely prevent a heart attack, stroke or a heart-related death in people who already have heart disease—but not diabetes.
Lilly bracing for demand crush for newly approved obesity drug
The Indianapolis-based drug company is ramping up manufacturing capacity to avoid possible shortages and to meet potentially huge demand in a nation where more than 40% of adults are classified as obese.